Market Overview

UPDATE: Oppenheimer Downgrades Zogenix to Perform Following Negative Panel

Related ZGNX
Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix
Zogenix Announces Departure of Chief Commercial Officer, Scott Shively

Oppenheimer reduced its rating on Zogenix (NASDAQ: ZGNX) from Outperform to Perform and removed its $3 price target.

Oppenheimer said, "On 12/7, ZGNX's Zohydro did not receive a positive recommendation from an FDA Advisory Committee, which cited safety concerns, mainly abuse potential and dependence. It appeared that the panel held Zohydro to a higher standard than other in-class drugs. As such, we do not anticipate that ZGNX will receive approval by the 3/1/13 PDUFA with potential approval likely delayed until abuse risks are mitigated. We believe ZGNX will continue to work with the FDA to improve upon the current REMS program, which the panel viewed as insufficient (owing mainly to its voluntary nature)."

Zogenix closed at $2.36 on Friday.

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ZGNX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters